Liquidia receives $50M from HCR after first commercial YUTREPIA sale and court win

Liquidia Corp

Received $50M from HCR after court denied preliminary injunction and first commercial sale of YUTREPIA.
Total funding under HCR agreement now $175M of $200M potential; $25M more available if net sales exceed $100M by June 30, 2026.
Payments to HCR capped at 175% of amounts funded; true-up due if IRR falls below 13% for this $50M tranche.
CFO says proceeds will accelerate launch execution, clinical pipeline, and manufacturing build-out.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.